Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...
In this Healio Video Perspective from Retina 2026, Sharon Fekrat, MD, FACS, FASRS, of Duke University, discusses the current ...
AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
Zacks Investment Research on MSN
Is BMY's deep pipeline the key to its next growth phase?
Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
Pharmaceutical Technology on MSN
JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement
AbbVie and RemeGen are the first companies to announce a deal at the J.P Morgan Healthcare Conference 2026, with more deals ...
Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results